NASDAQ:VRCAVerrica Pharmaceuticals Stock Price, Forecast & News

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VRCA stock has decreased by 41.4% and is now trading at $6.16.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Verrica Pharmaceuticals.

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Verrica Pharmaceuticals.

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.07.
View Verrica Pharmaceuticals' earnings history.

5 Wall Street analysts have issued 1 year target prices for Verrica Pharmaceuticals' stock. Their forecasts range from $10.00 to $18.00. On average, they expect Verrica Pharmaceuticals' stock price to reach $15.00 in the next year. This suggests a possible upside of 143.5% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals.

News headlines about VRCA stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Verrica Pharmaceuticals.

Verrica Pharmaceuticals saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,040,000 shares, an increase of 25.2% from the July 15th total of 830,400 shares. Based on an average trading volume of 95,300 shares, the short-interest ratio is currently 10.9 days. Approximately 8.1% of the shares of the stock are short sold.
View Verrica Pharmaceuticals' Short Interest.

Some companies that are related to Verrica Pharmaceuticals include Passage Bio (KROS), BIOFRONTERA AG/ADR (BFRA), ImmunoGen (IMGN), Applied Therapeutics (APLT), Collegium Pharmaceutical (COLL), Mirum Pharmaceuticals (MIRM), Tricida (TCDA), Akouos (AKUS), Vanda Pharmaceuticals (VNDA), ZIOPHARM Oncology (ZIOP), Aprea Therapeutics (APRE), Emisphere Technologies (EMIS), G1 Therapeutics (GTHX), Flexion Therapeutics (FLXN) and Eagle Pharmaceuticals (EGRX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Novan (NOVN), Pennsylvania R.E.I.T. (PEI), OrganiGram (OGI) and Zosano Pharma (ZSAN).

(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Verrica Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Kornitzer Capital Management Inc. KS (1.90%), Bank of New York Mellon Corp (0.13%), California Public Employees Retirement System (0.11%), Creative Planning (0.08%), Spouting Rock Asset Management LLC (0.06%) and UBS Group AG (0.03%). Company insiders that own Verrica Pharmaceuticals stock include Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White.
View institutional ownership trends for Verrica Pharmaceuticals.

VRCA stock was sold by a variety of institutional investors in the last quarter, including Spouting Rock Asset Management LLC, UBS Group AG, and Bank of New York Mellon Corp.
View insider buying and selling activity for Verrica Pharmaceuticals.

VRCA stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning, Kornitzer Capital Management Inc. KS, and California Public Employees Retirement System. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Linda Palczuk, Paul B Manning, Sean Stalfort, and Ted White.
View insider buying and selling activity for Verrica Pharmaceuticals.

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRCA stock can currently be purchased for approximately $6.16.

Verrica Pharmaceuticals has a market capitalization of $159.01 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.

The official website for Verrica Pharmaceuticals is www.verrica.com.

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]